Further development of the clinical potential of H2 relaxin

H2松弛素临床潜力的进一步开发

• 批准号: nhmrc : 1023078
• 负责人: A/Pr Richard Hughes
• 金额: $ 43.46万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-clinical-potential-h2-relaxin/110243
• 关键词: Further; development; clinical; potential; H2

The hormone relaxin mediates cardiovascular and kidney changes during pregnancy. These important functions have led to its current use in clinical trials for the treatment of acute heart failure, a condition affecting millions of patients worldwide. However, there is an urgent need for a longer lasting form of relaxin for prolonged treatment of patients. Our studies will focus on understanding the blood breakdown of the peptide to lead to the design of longer lasting relaxin analogues.

激素松弛素在怀孕期间介导心血管和肾脏的变化。这些重要的功能导致其目前用于治疗急性心力衰竭的临床试验，这种疾病影响着全球数百万患者。然而，迫切需要更持久形式的松弛素用于延长患者的治疗。我们的研究将集中在了解肽的血液分解，以设计更持久的松弛素类似物。